Affiliations 

  • 1 Yale University School of Medicine and Yale Cancer Center, New Haven, CT
  • 2 Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia
  • 3 Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria
  • 4 Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
  • 5 National Cancer Center Hospital East, Kashiwa, Japan
  • 6 Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil
  • 7 National Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
  • 8 Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
  • 9 University of Kansas Medical Center, Kansas City, KS
  • 10 Oslo University Hospital, Oslo, Norway
  • 11 Medical University of Vienna, Vienna, Austria
  • 12 Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Queensland, Australia
  • 13 Catalan Institute of Oncology, Badalona, Barcelona, Spain
  • 14 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 15 University Hospital, Zurich, Switzerland
  • 16 Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 17 Merck & Co Inc, Kenilworth, NJ
  • 18 The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom
J Clin Oncol, 2022 Jul 20;40(21):2321-2332.
PMID: 35333599 DOI: 10.1200/JCO.21.02198

Abstract

PURPOSE: The phase III KEYNOTE-048 (ClinicalTrials.gov identifier: NCT02358031) trial of pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) included planned efficacy analyses in the total population and in participants with programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥ 1 and CPS ≥ 20. To further characterize the predictive value of PD-L1 expression on outcome, we conducted efficacy analyses in the PD-L1 CPS < 1 and CPS 1-19 subgroups in KEYNOTE-048.

METHODS: Participants with R/M HNSCC and no prior systemic therapy for R/M disease were randomly assigned 1:1:1 to pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy. Post hoc efficacy analyses of the PD-L1 CPS < 1 and CPS 1-19 subgroups were performed.

RESULTS: Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]). For pembrolizumab-chemotherapy versus cetuximab-chemotherapy, the median overall survival was 11.3 versus 10.7 months in the PD-L1 CPS < 1 subgroup (HR, 1.21 [95% CI, 0.76 to 1.94]) and 12.7 versus 9.9 months in the CPS 1-19 subgroup (HR, 0.71 [95% CI, 0.54 to 0.94]).

CONCLUSION: Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression. PD-L1 CPS < 1 subgroup analysis was limited by small participant numbers. Results from the PD-L1 CPS 1-19 subgroup support previous findings of treatment benefit with pembrolizumab monotherapy and pembrolizumab-chemotherapy in patients with PD-L1 CPS ≥ 1 tumors. Although PD-L1 expression is informative, exploration of additional predictive biomarkers is needed for low PD-L1-expressing HNSCC.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications